Literature DB >> 7264920

Improved delivery through biological membranes XD: Percutaneous absorption and metabolism of methylsulfinylmethyl 2-acetoxybenzoate and related aspirin prodrugs.

T Loftsson, N Bodor.   

Abstract

Oxidative-reductive interconversion of the methylthiomethyl ester of aspirin and the corresponding sulfoxide and sulfone derivatives can be detected in rat liver homogenate, in addition to the extremely facile hydrolysis of these esters. The methylthiomethyl and methylsulfinylmethyl 2-acetoxybenzoates penetrate freshly excised hairless mice skin rather easily with the simultaneous hydrolysis of the two ester functions. Contrary to in vivo observations in dogs, where significant amounts of aspirin formed, the prodrugs cleave to salicylic acid and/or salicylate esters rather than aspirin.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7264920     DOI: 10.1002/jps.2600700710

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  5 in total

1.  Skin structure and metabolism: relevance to the design of cutaneous therapeutics.

Authors:  D A Bucks
Journal:  Pharm Res       Date:  1984-07       Impact factor: 4.200

2.  Soft drugs based on hydrocortisone: the inactive metabolite approach and its application to steroidal antiinflammatory agents.

Authors:  R J Little; N Bodor; T Loftsson
Journal:  Pharm Res       Date:  1999-06       Impact factor: 4.200

3.  Rational design of a dual-mode optical and chemical prodrug.

Authors:  Colin P McCoy; Clare Rooney; David S Jones; Sean P Gorman; Mark Nieuwenhuyzen
Journal:  Pharm Res       Date:  2006-11-16       Impact factor: 4.200

4.  Soft drugs. XX. Design, synthesis, and evaluation of ultra-short acting beta-blockers.

Authors:  H S Yang; W M Wu; N Bodor
Journal:  Pharm Res       Date:  1995-03       Impact factor: 4.200

5.  Percutaneous penetration of acyclovir through excised hairless mouse and rat skin: effect of vehicle and percutaneous penetration enhancer.

Authors:  H Okamoto; K Muta; M Hashida; H Sezaki
Journal:  Pharm Res       Date:  1990-01       Impact factor: 4.200

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.